Stewart Fisher - Feb 14, 2022 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
Chief Scientific Officer
Signature
/s/ Jolie Siegel, as Attorney-in-Fact
Stock symbol
CCCC
Transactions as of
Feb 14, 2022
Transactions value $
$0
Form type
4
Date filed
2/16/2022, 03:30 PM
Previous filing
Dec 10, 2021
Next filing
Apr 12, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CCCC Stock Option (Right to Buy) Award $0 +118K $0.00 118K Feb 14, 2022 Common Stock 118K $22.71 Direct F1
transaction CCCC Performance Restricted Stock Units Award $0 +26.3K $0.00 26.3K Feb 14, 2022 Common Stock 26.3K Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2022.
F2 Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining 21,750 PRSUs shall vest upon satisfaction of certain discovery and clinical milestones.